Synthesis of bis-thiazolidin-4-ones from N,N,N″-(1,ω-alkanediyl)bis(N″-organylthiourea) derivatives

Alaa A. Hassan; Kamal M.A. El-Shaieb; Amal S. Abd El-Aal; Stefan Bräse; Martin Nieger

doi:10.1515/znb-2014-0226

Artikel Öffentlich zugänglich

Synthesis of bis-thiazolidin-4-ones from N,N,N″-(1,ω-alkanediyl)bis(N″-organylthiourea) derivatives

Alaa A. Hassan , Kamal M.A. El-Shaieb , Amal S. Abd El-Aal , Stefan Bräse und Martin Nieger

Veröffentlicht/Copyright: 20. März 2015

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Zeitschrift für Naturforschung B Band 70 Heft 4

Abstract

A new series of (2Z,2′E)-dimethyl 2,2′-[(2Z,2′Z)-3,3′-(alkanediyl)bis(4-oxo-2-iminothiozolidin-3-yl-5-ylidene)]acetates has been synthesized by the reaction of N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives with dimethyl acetylenedicarboxylate. The structures were established by spectroscopic data, elemental analyses, and single crystal X-ray crystallography. A rationale for the formation of the products is presented.

Keywords: bis-thiazolidin-4-ones; dimethyl acetylenedicarboxlate; N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives

1 Introduction

Thiazolidinones are known to be privileged small ring heterocycles because they exhibit different types of biological activities [1–6]. The 4-thiazolidinone ring system comprises a large number of biologically active compounds that have been evaluated for their anticonvulsant [7, 8], antidiarrheal [9], antiplatelet activating [10], antimicrobial [3, 10, 11], anti-HIV [12–15], and anticancer [16–18] activities. Several methods for the stereoselective synthesis of thiazolidin-4-ones are available in the literature [19–29].

Conversely, N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives 1 constitute a core structure in various synthetic heterocyclic compounds [30]. In recent years, microwave assisted or conventional thermal intramolecular heterocyclization reactions of compound 1 have been reported [31]. Imidazolidine, diazepine, and thiadiazepane derivatives were isolated upon treating ethenetetracarbonitrile with bithiourea derivatives 1 [32].

Recently, it has been reported that the one pot, pseudo-five-component reaction of an aliphatic diamine, isothiocyanatobenzene and dialkyl but-2-ynedioate at room temperature in anhydrous CH₂Cl₂ gave bis[2(arylimino)-1,3-thiazolidin-4-ones] [33].

The present investigation deals with the synthesis of some new (2Z,2′E)-dimethyl 2,2′-[(2Z,2′Z)-3,3′-(alkanediyl-bis(4-oxo-2-substituted imino)thiazolidin-3-yl-5-ylidene)]- diacetates 3a–h in moderate yields from N,N″-(1-ω-alkanediyl)-bis(N′-organylthiourea) derivatives 1a–h.

2 Results and discussion

To obtain new bis(thiazolidin-4-ones) 3a–h, a mixture of a doubled molar amount of dimethyl acetylenedicarboxylate (DMAD, 2) with 1 mole of the respective bithiourea derivatives 1a–h was heated for 4–12 h at reflux in absolute ethanol. A yellow solid of 3a–h was obtained, which, after spectroscopic characterization, was confirmed to be the proposed compound (Scheme 1).

Scheme 1:

Synthesis of bis(4-oxo-2-iminothiazolidine-5-ylidene)acetates.

The synthesized compounds were characterized by their IR, ¹H NMR, ¹³C NMR, and mass spectral data, as well as single crystal X-ray crystallography.

The IR spectrum of 3g as an example was characterized by the presence of a new C=O band at 1730 cm^–1, which agrees with those found for other thiazolidin-4-ones [34–36]. The ester carbonyl (C=O) and conjugated double bond (C=C) absorption bands were observed at 1695 and 1620 cm^–1, respectively. The N–H bands of bithiourea derivatives 1a–h were not evident in the IR spectra of 3a–h, whereas an absorption band at 1640 cm^–1, attributed to the C=N stretching vibration, was observed for 3g as an example.

The ¹H NMR chemical shifts of compounds 3a–h supported the proposed structure. In 3g, signals assigned to N-(CH₂)₃-N, were detected at δ = 2.35 and 4.00 ppm, whereas singlet signals were observed at 3.75 and 6.88 ppm due to OCH₃ and vinyl-CH, respectively, in addition to phenyl protons. The absence of resonances assigned to NH, N″H, HN′-phenyl protons of 1a–h supported the exact structure.

In the ¹³C NMR spectra of 3a–h, the prominent signals corresponding to the carbons of the thiazolidin-4-one ring in all compounds were observed. The ¹³C NMR spectrum of 3g showed five signals at δ = 166.28, 164.89, 150.82, 141.52, and 116.16 ppm, due to C=O (ester), C=O (ring), thiazolidinone C-2, thiazolidinone C-5, and vinyl-CH respectively.

According to elemental analyses and mass spectrometry, a net release of methanol (M.W. 32) had occurred. There are possibilities for formation of various isomers that would behave very similarly spectroscopically (Fig. 1). Similarly, all products observed are formed from one of the four labile 1:1 adducts A–D (Fig. 1).

Fig. 1:

Structures of putative intermediates A–D.

The molecular structure of 3g was established by a single crystal X-ray analysis (Fig. 2). The thiazolidinone ring and the adjacent benzene rings adopt a twisted geometry and the angle between the least-squares planes of the thiazolidine ring and the benzene ring are 97° (C1, C2, S3 C4, N5 and C42, C43, C44, C45, C46, C47) and 55° (N9, C10, C11, S12, C13 and C132, C133, C134, C135, C136, C137), while the thiazolidine ring and the acetate are coplanar. The X-ray structure analysis confirms a cisoid geometry between the vinylic CH bond and the thiazolidine carbonyl group.

Fig. 2:

Molecular structure of 3g in the crystal with displacement parameters drawn at the 50 % probability level. The crystallographic numbering does not reflect the systematic IUPAC numbering.

The formation of the products 3a–h may be rationalized as an initial attack by SH group of 1a–h at the C≡C triple bond of 2 to give the adduct C. Elimination of two molecules of MeOH affords bis(thiazolidinones) 3a–h (Scheme 2).

Scheme 2:

Rational for formation of 3a–h.

In conclusion, an efficient cyclization protocol for N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives with dimethyl acetylenedicarboxylate to a new series of bis(thiazolidin-4-ones) has been developed. In a different manner to the reported heterocyclization of the bithioureas [30, 31], the present reaction course has been found to be independent on the length of the alkanediyl chain.

3 Experimental section

All melting points were determined using open capillaries on a Gallenkamp melting point apparatus (Weiss-Gallenkamp, Loughborough, UK). The IR spectra were recorded with a Shimadzu 408 (Shimadzu Corporation, Kyoto, Japan) instrument using potassium bromide. The 400 MHz ¹H NMR and 100 MHz ¹³C NMR were recorded on a Bruker AM 400 spectrometer (Bruker BioSpin, Karlsruhe, Germany) with tetramethylsilane as the internal standard; s = singlet, t = triplet, q = quartet, m = multiplet. The ¹³C NMR signals were assigned on the basis of DEPT 135/90 spectra. The mass spectra (70 eV, electron impact mode) were recorded on a Finnigan MAT (Germany) instrument. Elemental analyses were carried out at the Microanalytical Center, Cairo University, Egypt. Reactions were monitored by thin-layer chromatography (TLC) on pre-coated silica gel HF 254 plates from Merck, and compounds visualized by exposure to UV light. Preparative layer chromatography (plc) used air-dried 1.0 mm thick layers of slurry of silica gel (Merck PF254) on 48 cm wide and 20 cm high glass plates using the solvents listed. Zones were detected by quenching of indicator fluorescence upon exposure to 254 nm light and eluted with acetone.

3.1 Starting materials

N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives 1a–h were prepared by the reaction of the diamine (1,2-diaminoethane, 1,3-diaminopropane) with ethyl-, phenyl-, benzyl-, or allylisothiocyanate in DMF according to published procedures in literature: 1a [37], 1b [38], 1c [39], 1d [30], 1e [40], 1f [31], 1g [41], and 1h [42]. DMAD (2) was bought from Fluka.

3.2 Reaction of N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives 1a–h with DMAD(2)

Into a 100 mL round bottom flask containing (284 mg, 2 mmol) of 2 in 15 mL of absolute ethanol, a solution of 1 mmol of 1a–h in absolute ethanol (20 mL) was added dropwise with stirring. The mixture was gently refluxed with stirring for 4–12 h (4 h for 1b and 1d; 9 h for 1c; 10 h for 1a and 1e; 12 h for 1f). The reactions were monitored by TLC analyses. The solvent was concentrated and the residue was subjected to preparative layer chromatography (plc) using toluene-ethyl acetate (5:1) as the developing solvent to give one main zone and numerous other ones.

3.3 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(ethane-1,2-diyl)bis-(2-ethylimino)-4-oxothiazolidin-3-yl-5-ylidene)]diacetate (3a)

Yellow crystals (300 mg, 66 %), m. p. 176–177 °C (acetonitrile). – IR (KBr): υ = 2990 (aliph. CH), 1720, 1700 (C=O), 1640 (C=N), 1615 (C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 6.8 (s, 2H, 2 vinyl CH), 3.86 (s, 6H, 2 OCH₃), 3.55 (s, 4H, 2 CH₂N), 3.35 (q, 4H, J = 7.64 Hz, 2 CH₂), 1.15–1.30 (t, 6H, J = 7.64 Hz, 2 CH₃). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.5 (ester C=O), 164.72 (cyclic C=O), 150.10 (thiazolidine C-2), 141.33 (thiazolidine C-5), 115.42 (vinyl CH), 52.93 (OCH₃), 49.14 (CH₂N), 40.18 (CH₂), 15.79 (CH₃). – MS (EI, 70 eV): m/z (%) = 452 (75) [M]⁺, 240 (100) [M–C₈H₉N₂O₃S]⁺, 226 (20) [C₉H₁₁N₂O₃S]⁺, 212 (12) [M–C₁₀H₁₃N₂O₃S]⁺, 87 (5) [M–C₁₅H₉N₃O₆S]⁺, 43 (5) [C₂H₅N]⁺. – C₁₈H₂₂N₄O₆S₂ (452.52): calcd. C 47.56, H 4.88, N 12.33, S 14.11; found: C 47.69, H 4.97, N 12.19, S 13.95.

3.4 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(ethane-1,2-diyl)bis-(2-allylimino)-4-oxothiazolidin-3-yl-5-ylidene)]diacetate (3b)

Yellow crystals (296 mg, 62 %), m. p. 154–155 °C (acetonitrile). – IR (KBr): υ = 2950 (aliph. CH), 1720, 1695 (C=O), 1645 (C=N), 1610 (C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 6.85 (s, 2H, 2 vinyl CH), 5.92–5.93 (m, 2H, allyl CH=), 5.25–5.27 (m, 4H, allyl CH₂=), 4.50 (s, 4H, allyl CH₂N), 3.85 (s, 6H, 2 OCH₃), 3.52 (s, 4H, 2 CH₂N). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.36 (ester C=O), 164.42 (cyclic C=O), 149.54 (thiazolidine C-2), 141.28 (thiazolidine C-5), 134.29 (allyl CH=), 118.31 (allyl CH₂), 115.25 (vinyl CH), 54.60 (OCH₃), 49.68 (CH₂-N), 44.22 (allyl CH₂N). – MS (EI, 70 eV): m/z (%) = 478 (44) [M]⁺, 447 (10) [M–CH₃O]⁺, 267 (38) [M–C₈H₇N₂O₃S]⁺, 239 (27) [M–C₁₀H₁₁N₂O₃S]⁺, 152 (100) [M–C₁₃H₁₆N₃O₅S]⁺, 137 (41) [M–C₁₄H₁₇N₂O₄S₂]⁺. – C₂₀H₂₂N₄O₆S₂ (478.54): calcd. C 50.20, H 4.63, N 11.71, S 13.40; found: C 50.06, H 4.71, N 11.84, S 13.28.

3.5 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(ethane-1,2-diyl)bis-(4-oxo-2- phenylimino)thiazolidin-3-yl-5-ylidene)]diacetate (3c)

Yellow crystals (368 mg, 67 %), m. p. = 166–167 °C (acetonitrile). – IR (KBr): υ = 3080 (arom. CH), 2970 (aliph. CH), 1725, 1695 (C=O), 1640 (C=N), 1620 (arom. C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 7.40–7.32 (m, 2H, arom. H), 7.30–7.21 (m, 6H, arom. H), 7.18–7.10 (m, 2H, arom. H), 6.80 (s, 2H, 2 vinyl CH), 3.80 (s, 6H, 2 OCH₃), 3.58 (s, 4H, 2 CH₂N). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.49 (ester C=O), 164.88 (cyclic C=O), 150.96 (thiazolidine C-2), 141.92 (thiazolidine C-5), 130.11, 129.37 (arom. C), 129.05, 129.29, 128.88, 127.88, 125.79, 125.99 (arom. CH), 115.76 (vinyl CH), 53.48 (OCH₃), 41.45 (ethane CH₂N). – MS (EI, 70 eV): m/z (%) = 550 (45) [M]⁺, 289 (100) [M–C₁₄H₁₃N₂O₃S]⁺, 135 (35) [M–C₁₉H₁₇N₃O₆S]⁺, 91 (10) [C₆H₅N]⁺. – C₂₆H₂₂N₄O₆S₂ (550.61): calcd. C 56.72, H 4.03, N 10.18, S 11.65; found: C 56.84, H 3.91, N 10.05, S 11.80.

3.6 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(ethane-1,2-diyl)bis-(2-benzylimino)-4-oxo-thiazolidin-3-yl-5-ylidene)]diacetate (3d)

Yellow crystals (360 mg, 62 %), m. p. 160–161 °C (acetonitrile). – IR (KBr): υ = 3110 (arom. CH), 2960 (aliph. CH), 1720, 1700 (C=O), 1645 (C=N), 1610 (arom. C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 7.34 (m, 10H, arom. H), 6.85 (s, 2H, 2 vinyl CH), 4.86 (s, 4H, 2 benzyl CH₂), 3.86 (s, 6H, 2 OCH₃), 3.65 (s, 4H, 2 CH₂N). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.44 (ester C=O), 164.75 (cyclic C=O), 150.24 (thiazolidine C-2), 141.26 (thiazolidine C-5), 135.63 (arom. C), 135.61, 128.86, 128.59, 128.47, 128.38, 127.24 (arom. CH), 115.81 (vinyl CH), 56.16 (benzyl CH₂), 52.93 (OCH₃), 41.82 (ethane CH₂N). – MS (EI, 70 eV): m/z (%) = 578 (91) [M]⁺, 461 (23) [M–C₈H₇N]⁺, 289 (42) [M–C₁₄H₁₃N₂O₃S]⁺, 91 (100) [PhCH₂]⁺. – C₂₈H₂₆N₄O₆S₂ (578.66): calcd. C 58.12, H 4.53, N 9.68, S 11.08; found: C 57.97, H 4.62, N 9.78, S 10.94.

3.7 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(propane-1,3-diyl)bis-(2-ethylimino)-4-oxo-thiazolidin-3-yl-5-ylidene)]diacetate (3e)

Yellow crystals (294 mg, 63 %), m. p. 105–106 °C (acetonitrile). – IR (KBr): υ = 2970 (aliph. CH), 1725, 1700 (C=O), 1645 (C=N), 1605 (C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 6.88 (s, 2H, vinyl CH), 3.86 (s, 6H, 2 OCH₃), 3.81 (t, 4H, J = 7.62 Hz, 2 CH₂N), 2.5 (m, 2H, propane CH₂), 3.55 (q, 4H, J = 7.66 Hz, CH₂), 1.30 (t, 6H, J = 7.66 Hz, 2CH₃). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.51 (ester C=O), 164.78 (cyclic C=O), 148.80 (thiazolidine C-2), 141.47 (thiazolidine C-5), 115.15 (vinyl CH), 52.48 (OCH₃), 49.78 (CH₂), 40.95 (propane CH₂N), 28.52 (propane CH₂), 15.89 (CH₃). – MS (EI, 70 eV): m/z (%) = 468 (100) [M]⁺, 437 (10) [M–CH₃O]⁺, 255 (75) [M–C₈H₉N₂O₃S]⁺, 227 (35) [M–C₁₀H₁₃N₂O₃S]⁺, 213 (12) [M–C₁₁H₁₅N₂O₃S]⁺, 59 (7) [COOMe]⁺. – C₁₉H₂₄N₄O₆S₂ (468.55): calcd. C 48.70, H 5.16, N 11.96, S 13.69; found: C 48.59, H 5.24, N 12.08, S 13.82.

3.8 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(propane-1,3-diyl)-bis(2-allylimino)-4-oxo-thiazolidin-3-yl-5-ylidene)]diacetate (3f)

Yellow crystals (323 mg, 66 %), m. p. 153–154 °C (acetonitrile). – IR (KBr): υ = 2980 (aliph. CH), 1735, 1715 (C=O), 1640 (C=N), 1610 (C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 6.84 (s, 2H, 2 vinyl CH), 5.92 (m, 2H, allyl CH=), 5.20 (m, 4H, allyl CH₂=), 4.38 (m, 4H, allyl CH₂N), 3.78 (s, 6H, 2 OCH₃), 3.48 (t, 4H, J = 7.61 Hz, CH₂N), 2.45 (m, 2H, propane CH₂). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.45 (ester C=O), 164.72 (cyclic C=O), 149.55 (thiazolidine C-2), 141.27 (thiazolidine C-5), 134.38 (allyl CH=), 118.54 (allyl CH₂=), 115.46 (vinyl CH), 54.60 (OCH₃), 49.53 (allyl CH₂N), 41.03 (propane CH₂N), 28.50 (propane CH₂). – MS (EI, 70 eV): m/z (%) = 492 (100) [M]⁺, 461 (10) [M–CH₃O]⁺, 267 (35) [M–C₉H₉N₂O₃S]⁺, 225 (15) [M–C₁2H₁₅N₂O₃S]⁺, 99 (54) [M–C₁₇H₁₉N₃O₆S]⁺, 59 (38) [COOMe]⁺. – C₂₁H₂₄N₄O₆S₂ (492.57): calcd. C 51.21, H 4.91, N 11.37, S 13.03; found: C 51.36, H 5.04, N 11.21, S 12.94.

3.9 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′-(propane-1,3-diyl)bis-(4-oxo-2- phenylimino)thiazolidin-3-yl-5-ylidene)]diacetate (3g)

Yellow crystals (346 mg, 61 %), m. p. 176–177 °C (acetonitrile). – IR (KBr): υ = 2960 (aliph. CH), 1730, 1695 (C=O), 1640 (C=N), 1620 (arom. C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 7.18–7.22 (m, 6H, arom. H), 7.12–7.14 (m, 4H, arom. H) 6.88 (s, 2H, vinyl CH), 4.00 (t, 4H, J = 7.65 Hz, 2 CH₂N), 3.75 (s, 6H, 2 OCH₃), 2.35 (m, 2H, propane CH₂). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.28 (ester C=O), 164.89 (cyclic C=O), 150.82 (thiazolidine C-2), 141.52 (thiazolidine C-5), 129.64, 129.36, 129.07, 125.26, 121.06, 120.73 (arom. CH), 116.16 (vinyl CH), 52.52 (OCH₃), 40.57 (CH₂N), 25.75 (propane CH₂). – MS (EI, 70 eV): m/z (%) = 564 (91) [M]⁺, 303 (100) [M–C₁₂H₉N₂O₃S]⁺, 289 (26) [M–C₁₃H₁₁N₂O₃S]⁺, 135 (76) [M–C₂₀H₁₉N₃O₆S]⁺, 91 (21) [C₆H₅N]⁺. –C₂₇H₂₄N₄O₆S₂ (564.63): calcd. C 57.43, H 4.28, N 9.92, S 11.36; found: C 57.55, H 4.36, N 10.12, S 11.22.

3.10 (2Z,2′E)-dimethyl-2,2′-[(2Z,2′Z)-3,3′- (propane-1,3-diyl)-bis(2-benzylimino)-4-oxo-thiazolidin-3-yl-5-ylidene)]diacetate (3h)

Yellow crystals (377 mg, 64 %), m. p. 181–182 °C (acetonitrile). – IR (KBr): υ = 3080 (arom. CH), 2990 (aliph. CH), 1722, 1695 (C=O), 1645 (C=N), 1610 (arom. C=C) cm^–1. – ¹H NMR (400 MHz, CDCl₃, 20 °C, TMS): δ = 7.41–7.44 (m, 2H, arom. H), 7.20–7.32 (m, 8H, arom. H), 6.90 (s, 2H, vinyl CH), 4.70 (s, 4H, benzyl CH₂), 3.85 (s, 6H, 2 OCH₃), 3.52 (t, 4H, J = 7.60 Hz, CH₂N), 2.28 (m, 2H, propane CH₂). – ¹³C NMR (100 MHz, CDCl₃): δ = 166.44 (ester C=O), 164.75 (cyclic C=O), 149.70 (thiazolidine C-2), 141.21 (thiazolidine C-5), 138.84, 135.77 (arom. C), 129.01, 128.82, 128.30, 127.90, 127.46, 127.41 (arom. CH), 115.52 (vinyl CH), 56.06 (OCH₃), 49.73 (benzyl CH₂), 41.18 (propane CH₂N), 28.66 (propane CH₂). – MS (EI, 70 eV): m/z (%) = 592 (35) [M]⁺, 502 (10) [M–PhCH₂]⁺, 289 (16) [M–C₁₅H₁₅N₂O₃S]⁺, 91 (100) [PhCH₂]⁺. – C₂₉H₂₈N₄O₆S₂ (592.69): calcd. C 58.77, H 4.76, N 9.45, S 10.82; found: C 58.64, H 4.83, N 9.56, S 10.94.

3.11 Single-crystal X-ray structure determination of 3g

Single crystals were obtained by recrystallization from acetonitrile. The single crystal X-ray diffraction study was carried out on a Bruker–Nonius Kappa CCD diffractometer at T = 123 K using MoK_α radiation (λ = 0.71073 Å). Direct Methods (shelxs-98) [43] were used for structure solution and refinement was carried out using Shelxl-2013 [43] (full-matrix least-squares on F²). Hydrogen atoms were localized by different Fourier synthesis map and refined using a riding model. A semi-empirical absorption correction was applied. Crystal structure data: C₂₇H₂₄N₄O₆S₂, M_r = 564.62, yellow rods, crystal size 0.50 × 0.08 × 0.04 mm³, monoclinic space group P2₁/n (no. 14), a = 8.992(1), b = 10.093(1), c = 30.033(3) Å, β = 96.28(1)°, V = 2709.3(5) Å³, Z = 4, d_calcd. = 1.384 mg m^–3, F(000) = 1176 e, μ(MoK_α) = 0.25 mm^–1, 20 956 measured reflections, 2 θ_max = 55°, 6139 independent, R_int = 0.046, 222 ref. parameters, R₁ (for 4839 data with I > 2 σ(I)] = 0.056, wR₂ (all data) = 0.121, S = 1.16, largest diff. peak/hole = 0.33/–0.30 e A^–3.

CCDC 958575 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Corresponding author: Alaa A. Hassan, Faculty of Science, Chemistry Department, Minia University, 61519 El-Minia, A. R. Egypt, Fax: +2-086-2363011, E-mail: alaahassan2001@mu.edu.eg, alaahassan2001@yahoo.com

References

[1] A. Saeed, N. Abbas, M. Flőrke, J. Braz. Chem. Soc. 2007, 18, 559.Suche in Google Scholar

[2] Y. Suzaki, K. Osakada, Asian J. Chem. 2006, 18, 331.Suche in Google Scholar

[3] S. N. Pandeya, D. Sriram, G. Nath, E. Declercq, Eur. J. Pharm. Sci. 1999, 9, 25.Suche in Google Scholar

[4] M. Abhinit, M. Ghodke, N. A. Pratima, Int. J. Pharm. Pharm. Sci. 2009, 1, 47.Suche in Google Scholar

[5] D. Prasad, A. Kumar, P. K. Shukl, M. Nath, Org. Med. Chem. Lett. 2011, 1, 1.Suche in Google Scholar

[6] E. Tatar, I. Küçükgüzel, E. DeClercq, R. Krishman, N. Kaushik-Basu, Marmara Pharm. J. 2012, 16, 181.Suche in Google Scholar

[7] K. M. Amin, A. D. E. Rahman, Y. A. Al-Eryani, Bioorg. Med. Chem. 2008, 16, 5377.Suche in Google Scholar

[8] A. Agarwal, S. Lata, K. K. Saxena, N. K. Srivastava, A. Kumar, Eur. J. Med. Chem. 2006, 41, 1223.Suche in Google Scholar

[9] M. V. Diurno, O. Mazzoni, A. A. Izzo, A. Botagnese, Il Farmaco 1997, 52, 237.Suche in Google Scholar

[10] Y. Tanabe, H. Yamamoto, M. Murakami, K. Yanagi, Y. Kubota, H. Okumura, Y. Sanemitsu, G. Suzukama, J. Chem. Soc. Perkin Trans. 1, 1995, 7, 935.10.1039/p19950000935Suche in Google Scholar

[11] M. R. Shiradkar, K. K. Murahari, H. R. Gangadasu, T. Suresh, C. A. Kalyan, D. Panchal, R. Kaur, P. Burange, J. Ghogare, V. Mokale, M. Raut, Bioorg. Med. Chem. 2007, 15, 3997.Suche in Google Scholar

[12] S. K. Srivastava, S. D. Srivastava, Eur. J. Med. Chem. 2010, 45, 3541.Suche in Google Scholar

[13] R. K. Rawal, Y. S. Prabhakar, S. B. Katti, E. DeClereq, Bioorg. Med. Chem. 2005, 13, 6771.Suche in Google Scholar

[14] J. Balzarini, B. Orzeszko, J. K. Maurin, A. Orzesko, J. Med. Chem. 2007, 42, 993.Suche in Google Scholar

[15] M. L. Barreca, A. Chimirri, L. De Luca, A. Monforte, P. Monforte, A. Rao, M. Zappalà, J. Balzarini, E. DeClercq, C. Pannecouque, M. Witvrouw, Bioorg. Med. Chem. Lett. 2001, 11, 1793.Suche in Google Scholar

[16] Z. Hongyu, W. Shuhong, Z. Shumei, L. Aifeng, S. Ying, L. Rongshi, Z. Ying, E. Sean, W. S. Peter, F. Bingliang, Z. Bin, Y. Bing, J. Med. Chem. 2008, 51, 1247.Suche in Google Scholar

[17] V. Gududuru, E. Hurh, J. T. Dalton, D. D. Miller, Bioorg. Med. Chem. Lett. 2004, 14, 5289.Suche in Google Scholar

[18] A. Insuasty, J. Ramirez, M. Raimondi, C. Echeverry, J. Quiroga, R. Abonia, M. Nogueras, J. Cobo, M. V. Rodiguez, S. A. Zacchino, B. Insuasty, Molecules 2013, 18, 5482.10.3390/molecules18055482Suche in Google Scholar

[19] D. R. Stlanrent, Q. Gao, D. D. Wu, M. H. Serrano-Wu, Tertrahedron Lett. 2004, 45, 1907.Suche in Google Scholar

[20] A. Gürsoy, N. Terzioglu, Turk. J. Chem. 2005, 29, 247.Suche in Google Scholar

[21] P. Vicini, A. Geonikaki, K. Anastasia, M. Incerti, F. Zani, Bioorg. Med. Chem. 2006, 14, 3859.Suche in Google Scholar

[22] Z. Jieping, J. Blanchet, Tetrahedron Lett. 2004, 45, 4449.Suche in Google Scholar

[23] J. F. Dubreuil, J. P. Bazureau, Tetrahedron 2003, 59, 6121.10.1016/S0040-4020(03)00954-2Suche in Google Scholar

[24] M. A. P. Martins, C. P. Frizzo, D. M. Moreira, N. Zanatta, H. G. Bonacor So, Chem. Rev. 2008, 108, 2015.Suche in Google Scholar

[25] A. Dandia, R. Singh, S. Khaturia, C. Mérienne, G. Morgant, A. Loupy, Bioorg. Med. Chem. 2006, 14, 2409.Suche in Google Scholar

[26] M. Erdélyi, Topics Heterocycl. Chem. 2006, 1, 79.Suche in Google Scholar

[27] A. A. Hassan, Y. R. Ibrahim, E. M. El-Sheref, A. B. Brown, J. Heterocycl. Chem. 2012, 49, 1054.Suche in Google Scholar

[28] A. A. Hassan, Y. R. Ibrahim, E. M. El-Sheref, A. A. Aly, S. Bräse, A. B. Brown, J. Heterocycl. Chem. 2012, 49, 1380.Suche in Google Scholar

[29] A. A. Hassan, E. M. El-Sheref, J. Heterocycl. Chem. 2010, 47, 764.Suche in Google Scholar

[30] A. A. Hassan, A. E. Mourad, K. M. El-Shaieb, A. H. Abou-Zied, D. Döpp, Heteroat. Chem. 2003, 14, 535.Suche in Google Scholar

[31] A. A. Hassan, D. Döpp, J. Heterocycl. Chem. 2006, 43, 593.Suche in Google Scholar

[32] A. A. Hassan, A. E. Mourad, K. M. El-Shaieb, A. H. Abou-Zied, Z. Naturforsch. 2004, 59b, 910.Suche in Google Scholar

[33] A. Alizadeh, Z. Noaparast, H. Sabahno, N. Zohreh, Helv. Chim. Acta. 2010, 93, 1401.Suche in Google Scholar

[34] R. Markovic, M. M. Pergal, M. Baranac, D. Stanisavljev, M. Stojanvic, Arkivoc 2006, ii, 83.10.3998/ark.5550190.0007.209Suche in Google Scholar

[35] S. Bondock, W. Khalifa, A. A. Fadda, Eur. J. Med. Chem. 2007, 42, 948.Suche in Google Scholar

[36] M. Ashok, B. S. Holla, N. S. Kumari, Eur. J. Med. Chem. 2007, 42, 380.Suche in Google Scholar

[37] H. Nägele, Monatsh. Chem. 1912, 33, 941.Suche in Google Scholar

[38] L. T. Mizrakh, L. Yu. Polonskaya, A. N. Gvozdetskii, A. M. Vosil’ev, T. M. Ivanova, N. I. Lisina, Khim-Farm Zn. 1987, 21, 322; Chem. Abstr. 1988, 108, 21771r.Suche in Google Scholar

[39] F. D’Angeli, A. Bandel, V. Giormani, J. Org. Chem. 1963, 28, 1596.Suche in Google Scholar

[40] T. Yabuuchi, M. Hisaki, M. Matuda, R. Kimura, Chem. Pharm. Bull. 1975, 23, 663.Suche in Google Scholar

[41] K.-D. Müller, U. W. Gerwarth, J. Organomet. Chem. 1976, 110, 15.Suche in Google Scholar

[42] W. Guendel, Dehydag Deutsche Hydrierwerke GmbH, German Pat.1183069, 1964; Chem. Abstr. 1965, 62, 5198e.Suche in Google Scholar

[43] G. M. Sheldrick, Acta Crystallogr. 2008, A64, 112.Suche in Google Scholar

Received: 2014-9-19

Accepted: 2014-11-28

Published Online: 2015-3-20

Published in Print: 2015-4-1

Artikel in diesem Heft

https://doi.org/10.1515/znb-2014-0226

Schlagwörter für diesen Artikel

bis-thiazolidin-4-ones; dimethyl acetylenedicarboxlate; N,N″-(1,ω-alkanediyl)bis(N′-organylthiourea) derivatives